Videos / Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler
In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).
This educational activity was developed by Healthed at the request of and with funding from GSK.
PM-AU-FVU-OGM-220003 approved June 2022
Dementia & Chronic Disease – Practical Advice
Head and Neck Lumps
The NLCSP – Incidental Chest Findings – What Now? – A Focus on Interstitial Lung Abnormalities
Why are LAMAs Useful in Asthma Management